Commission Implementing Decision 2011/252/EU of 26 April 2011 allowing Member States to extend provisional authorisations granted for the new active substances ascorbic acid, ipconazole, spiromesifen, topramezone, and Pseudomonas sp. strain DSMZ 13134 (notified under document C(2011) 2668)
Proposed act with possible EEA relevance
Act under scrutiny by EEA EFTA
Draft Joint Committee Decision (JCD) under consideration
Entry into force of Joint Committee Decision (JCD) pending
Incorporated into the EEA Agreement and in force
Incorporated into the EEA Agreement but no longer in force
Legal status
Adopted EU legal act marked as EEA relevant by the EU but considered by the EEA EFTA States not to be relevant for incorporation into the EEA Agreement. There may be a number of reasons for this: the act may fall outside the scope of the EEA Agreement; it may have expired in the EU; or incorporation may not be required due to the contents or nature of the act. For some of the acts, discussions with the EU on their relevance are still ongoing. Area (EEA Agreement)
II Technical Regulations, Standards, Testing and Certification
II.XV Dangerous Substances
Legal documents
Commission Implementing Decision 2011/252/EU of 26 April 2011 allowing Member States to extend provisional authorisations granted for the new active substances ascorbic acid, ipconazole, spiromesifen, topramezone, and Pseudomonas sp. strain DSMZ 13134 (notified under document C(2011) 2668)
Durchführungsbeschluss der Kommission vom 26. April 2011 zur Ermächtigung der Mitgliedstaaten, die vorläufigen Zulassungen für die neuen Wirkstoffe Ascorbinsäure, Ipconazol, Spiromesifen, Topramezon und Pseudomonas sp. Stamm DSMZ 13134 zu verlängern (2011/252/EU)
History
26.04.2011
Adoption date in the EU
17.05.2011
Compliance date in the EU
Disclaimer: EEA-Lex is provided for information purposes only. The information is not guaranteed or promised to be current or complete and is not intended to replace any applicable legal sources.